Sandoz, a Novartis division, announced yesterday that it has acquired the UK-based medical and drug delivery device development company, Coalesce Product Development.
Through this deal, Sandoz has acquired the significant capabilities and assets of Coalesce, which will help it build on its existing portfolio of respiratory medicines and further improve patient access to these high-quality, complex therapies, a company statement said.
“Respiratory and complex generics are areas of relatively high unmet medical need, due largely to their comparatively high technical complexity,” said Richard Saynor, CEO, Sandoz, in the statement.
“At Sandoz, we have the experience and expertise to succeed in these fields and this acquisition offers us a significant new growth platform, particularly in the US and Europe, reinforcing our commitment to pioneer access for patients,” he added.